Hormone treatment of depression by Joffe, Russell T.
linical endocrine disorders have long been rec-
ognized to have psychiatric symptoms as a prominent
feature of their clinical presentation. Both hyper- and
hypofunction of the various endocrine glands have led
to a wide range of psychiatric symptoms and syndromes,
most commonly depression. Moreover, treatment of the
endocrine condition frequently results in resolution of
the psychiatric sequelae. These observations in endocrine
patients led to a comprehensive search for a hormonal
etiology for many psychiatric disorders, particularly
major depression and bipolar disorder. While this
research effort was largely unsuccessful, with the possi-
ble exception of perturbations of the adrenal axis in
major depression (see below), it did lead to substantial
enquiry into whether various hormones may have clin-
ically useful antidepressant efficacy in primary major
depression and, to a lesser extent, bipolar disorder. While
there are a number of case reports and small case series
documenting the antidepressant effects of a large num-
ber of hormones of various endocrine systems, there is a
limited database on just a few endocrine systems, which
include large open trials or randomized controlled trials.
This review will focus on these hormones which include:
￿ Hormones of the thyroid axis
￿ Gonadal steroids, which include testosterone in men
and gonadal steroids in women
￿ Melatonin
￿ Adrenal cortex hormones.
Thyroid hormones
Disorders of the thyroid axis have been closely linked to
psychiatric disorders.
1 While hyperthyroidism may pre-
sent with a heterogenous range of psychiatric symptoms
and syndromes, clinical hypothyroidism is invariably
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There is a well-established relationship between alterations
of various hormonal systems and psychiatric disorders, both
in endocrine and psychiatric patients. This has led to clini-
cal and research studies examining the efficacy of the dif-
ferent hormones for treatment of depression. These data
will be reviewed with particular regard to the thyroid,
gonadal, pineal, and adrenal cortex hormones. The data
generally provide limited, but varying evidence for the
antidepressant efficacy of these hormones.    
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1Although exten-
sive research has shown that the vast majority of patients
who present with major depression are euthyroid,
2 the
close association between depression and hypothy-
roidism led to a large database of studies in which vari-
ous hormones of the thyroid axis have been used to treat
depression as monotherapy or, more commonly, as
adjunct to standard antidepressants. Each of the hor-
mones of the thyroid axis will be reviewed.
Thyrotropin-releasing hormone
Thyrotropin-releasing hormone (TRH) is a hypothala-
mic peptide that regulates thyroid hormone secretion by
the thyroid gland through its effect on pituitary thyroid-
stimulating hormone (TSH) release. TRH is also a pep-
tide that occurs in brain, and has behavioral effects such
as reversal of drug-induced sedation or anesthesia and
stimulation of locomotor activity independent of its effect
on the thyroid.
3 Due to its stimulation of the thyroid axis,
as well as its independent effects on brain function, it has
been tested as an antidepressant. Most studies have
involved monotherapy, but there have also been studies
of the use of TRH together with electroconvulsive ther-
apy (ECT). These studies are reviewed in Table I.
TRH has been administered to patients intravenously
4-
12 and by oral routes
13-15 for depression. TRH has been
administered intravenously either as a single dose
4-6 or
as several doses over 3 to 4 days,
7-12 and transient anti-
depressant effects have been demonstrated.
4-15 However,
at least half of these studies have reported no or very
minimal therapeutic response to either intravenous or
oral TRH administered as monotherapy with duration
of treatment ranging from a single dose up to 30 days
(see Table I). Although a positive effect on depressed
mood cannot be definitively excluded, it is very difficult
to determine whether TRH has a significant therapeutic
role in the treatment of depression, because of its very
short duration of action and its stimulant effects inde-
pendent of the thyroid axis. Moreover, the transient
effects noted may have little to do with the thyroid axis
and may be a nonspecific activating effect of the neu-
ropeptide.
3 A later study used a randomized, double-
blind, placebo-controlled, crossover design in which
500 g of TRH was administered to eight depressed
patients who also received ECT for their depression.
TRH administered intravenously before the ECT led to
greater arousal and improved cognitive function when
compared with placebo. TRH did not have any substan-
tial effect on any seizure variables. This is a small study
that may suggest an alternative indication for TSH in the
treatment of depressed patients.
16
Thyrotropin 
Thyrotropin (TSH) is a pituitary hormone which stimu-
lates the thyroid gland, and thus would be expected to
achieve an effect similar to the administration of periph-
eral thyroid hormones for the treatment of depression.
17
One study to date has examined the antidepressant
effect of TSH. Prange and collaborators
18 administered
ten IU of TSH intravenously to 20 depressed women 1
day before beginning an antidepressant trial with the tri-
cyclic imipramine. The TSH-treated patients had a rapid
antidepressant response when compared with a placebo
control group. There are no replication studies, and
clearly the intravenous administration required would
limit the clinical utility of this hormone.
Tri-iodothyronine
The thyroid gland secretes two major hormones,
levothyroxine (T4) and tri-iodothyronine (T3).
17 T4 is
the major secretory product of the thyroid, and most T4
undergoes peripheral conversion to T3 in order to exert
its physiological action.
17T3 is the most broadly used thy-
roid hormone for treatment of depression, in contrast to
in endocrine patients where T4 is routinely used for thy-
roid replacement therapy.
17 In early studies, T3 was used
as monotherapy for the treatment of depressed
patients.
19,20 The data from these studies are largely
inconclusive, as they involved small patient samples,
inadequate clinical trial designs by current methodolog-
ical standards, and the use of heterogeneous patient
Pharmacological aspects
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Number of studies Total N Route of administration Duration Positive studies (TRH>placebo or =antidepressant)
3 36 IV Single dose 1
6 86 IV 3–4 days 1
3 52 Oral 7–30 days 1
Table I. Antidepressant effect of thyrotropin-releasing hormone (TRH).
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necessarily have major depression. There have been no
well-designed studies of T3 monotherapy to date, and,
therefore, its use as a single treatment for depression has
not gained any clinical use.
T3 has been used in three other ways in the treatment of
depression:
￿ In the initial few weeks of an antidepressant trial to
reduce the delay in antidepressant effect—acceleration
studies
￿ To improve treatment response in those who do not
respond adequately to an antidepressant trial—aug-
mentation studies
￿ To enhance antidepressant response by being used
throughout the antidepressant trial—enhancement
studies. 
Acceleration studies
These studies are reviewed in Table II. In the first of
these studies in 1969, Prange and collaborators
21 used T3
to accelerate the response to tricyclic antidepressants. In
several studies,
21,22,24 they demonstrated that if T3 was
administered at the outset of a tricyclic antidepressant
trial, there was a shorter lag in onset of therapeutic effect
as compared with placebo controls. This acceleration
effect was noted particularly in women as compared
with men.
21-26 In the next few years, several studies were
performed, some of which replicated these findings,
although some had negative results. These studies are
reviewed in Table II. All of these studies had major
methodological flaws, including small numbers of
patients, poorly defined patient groups, and relatively
brief duration of treatment, as well as the use of tricyclic
antidepressants rather than selective serotonin reuptake
inhibitors (SSRIs) at suboptimal doses by current stan-
dards. 
Augmentation studies
T3 has most commonly been used to augment response to
antidepressants in those who failed to respond to an anti-
depressant trial. These studies are reviewed in Table III.
These studies, whether open-label or controlled, generally
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Study N Dose T3 (μg/day) Antidepressant Day T3 added Duration Acceleration
Prange et al, 1969
21 20 25 Imipramine 5 28 +
Wilson et al, 1970
22 20 25 Imipramine 5 28 +
Coppen et al, 1972
23 15 25 Imipramine 1 28 +
Feighner et al, 1972
24 21 25 Imipramine 1 22 _
Wheatley, 1972
25 30 20 Amitryptiline 1 21 +
Wilson et al, 1974
26 19 Up to 62.5 Imipramine 3 28 +
Table II. T3 acceleration of antidepressant response.
Study N T3 dose (μg/day) Design Result
Earle, 1970
27 25 25 Open 14 of 25 responded
Ogura et al, 1974
28 44 20–30 Open 29 of 44 responded
Banki, 1975
29 52 20–40 Open 39 of 52 responded
Banki, 1977
30 33 20 Partially controlled 23 of 33 responded
Tsutsui et al, 1979
31 11 5–25 Open 10 of 11 responded
Goodwin et al, 1982
32 12 25–50 Double-blind 8 of 12 responded
Schwarcz et al, 1984
33 8 25–50 Open 4 of 8 responded
Gitlin et al, 1987
34 16 25 Double-blind, crossover T3 = placebo
Thase et al, 1989
35 20 25 Open 5 of 20 responded
Joffe and Singer, 1990
36 38 37.5 Double-blind 9 of 17 responded
Joffe et al, 1993
37 51 37.5 Double-blind, placebo-controlled 10 of 17 responded to T3, T3 > placebo, T3 = (lithium?)
Birkenhager et al, 1997
38 14 37.5 Open No response—all inpatients
Agid & Lerer, 2003
39 74 25-50 Open, added to SSRI 44/74 responded at 4 weeks
Table III. T3 augmentation of antidepressants.
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antidepressant trial will respond within 2 to 3 weeks after
the addition of 25 to 50  g of T3. The notable exception is
the study by Gitlin et al
34 who failed to find a significant
difference between T3 and placebo in the potentiation of
imipramine in 16 patients with major depression. This
study, however, involved a 2-week, double-blind, crossover
design, which can be problematic in evaluating antide-
pressant treatment response. Another study compared T3
augmentation to lithium augmentation in tricyclic antide-
pressant nonresponders.
37 Both augmentation strategies
were found to be comparable in a 2-week placebo-con-
trolled trial. This was the first study to directly compare
lithium and T3 in tricyclic augmentation, but later studies
did examine T3 versus lithium with SSRI nonrespon-
ders
41,42 (see Table III). In view of the limitations of the indi-
vidual studies involving tricyclics, a meta-analysis of these
studies concluded that T3 may increase response rates and
decrease severity of depression scores in patients refrac-
tory to tricyclic antidepressant treatment.
43 Patients with
T3 augmentation were approximately twice as likely to
respond as were controls. Recently, there has been emerg-
ing data on the use of T3 to augment SSRIs,
39-42 the most
commonly used antidepressants. The findings with the
SSRIs are generally consistent with those for the tricyclics.
Both open and controlled studies are generally positive,
and indicate that T3 may be an effective augmentation
agent for SSRI nonresponders. Recent data from the
STAR*D trial
42 showed that T3 augmentation had com-
parable response and remission rates to other augmenta-
tion options such as lithium, and a more favorable adverse
event dropout rate, despite the fact that response and par-
ticularly remission rates were low in all treatment groups.
Enhancement studies 
Cooper-Kazaz and collaborators
44 termed this group
enhancement studies, when T3 is added to an SSRI at
the outset of the antidepressant trial and is administered
throughout the acute treatment period. These studies are
summarized in Table IV. These studies provide virtually
no support for an acceleration effect of T3 when admin-
istered with SSRIs with only the Posternak et al
47 study
showing a trend toward acceleration. As far as enhance-
ment of SSRI response is concerned, the data are con-
flicting, with one positive,
46 one negative,
45 and one
trending study.
47The enhancement studies should prob-
ably be considered separately from the augmentation
studies. In the latter, patients have responded inade-
quately to an antidepressant and show some benefit with
T3 addition whereas with enhancement studies, subjects
include both potential responders and nonresponders to
antidepressants and the aim is to accelerate and enhance
rates of antidepressant response rather than to convert
nonresponders to antidepressant responders.
Thyroxine
This thyroid hormone has been used in two ways in the
treatment of mood disorders. First, it has been used as an
augmentation agent for the treatment of antidepressant
nonresponders, and, second, as a mood stabilizer for rapid-
cycling bipolar disorder. The latter will not be discussed.
T4 has received less attention as an augmentation agent,
as most of the initial studies were carried out using T3.
However, there is a limited database on the use of T4 aug-
mentation, and these studies are summarized in Table V.
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Study N T3 dose (μg/day) Design Result
Appelhof et al, 2004
45 113 25 vs 50 RCT, placebo-controlled T3 25 μg=T3 50 μg=Placebo
Cooper Kazaz et al, 2007
46 124 50 RCT, placebo-controlled Response T3=70%, Placebo=50%
Posternak et al, 2007
47 50 50 RCT, placebo-controlled Response T3=51%, Placebo=33%
Table IV. T3 Enhancement of antidepressants.
Study N Patients T4 Dose (μg/day) Design Response
Joffe and Singer, 1990
36 38 Unipolar major depression 150 Double-blind vs T3 4 of 21 responded to T4, T4 < T3
Bauer et al, 1998
48 17 Unipolar (or) bipolar depression 300–500 Open 10 of 17 showed full or partial response
Spoov and Lahdelma, 1998
49 22 Major depression 200 Crossover vs lithium T4 > lithium
Rudas et al, 1999
50 9 Chronic depression and dysthymia 150–300 Open 6 of 9 full or partial response
Lojko and Rybakowski, 2007
51 17 Unipolar and bipolar depression 100 Open, on SSRI 11 remission and 16 response
Table V. Antidepressant augmentation with T4. T3, tri-iodothyronine; T4, thyroxine; RCT, randomized controlled trial; SSRI, selective serotonin reup-
take inhibitor
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These studies generally involve open designs using various
diagnoses, including both unipolar and bipolar subjects in
one study
48 and chronic depression or dysthymic patients
in another study.
50 All involve small sample designs.
Nonetheless, in each of these studies, T4 showed augmen-
tation effects in antidepressant nonresponders. 
The efficacy of T4 and its comparable efficacy to T3
remain unresolved issues. A large-scale, well-designed,
placebo-controlled study directly comparing the efficacy
T3 and T4 in SSRI nonresponders with major depression
would address this important issue.
In conclusion, the database on thyroid hormone treat-
ment provides mixed findings in studies, often with
methodological limitations and inconclusive data. The
strongest evidence is for an antidepressant augmenta-
tion effect of T3 in antidepressant nonresponders, but
the use of T3 in other ways to accelerate and enhance
antidepressant treatment, as well as the clinical utility of
other hormones of the thyroid axis, require further study.
In addition, issues such as tolerability, long-term safety,
and duration, as well as dose of treatment need to be
addressed. The doses employed in all these studies are
less than the amount of endogenous T3 daily production
so that there is little risk of induction of clinical hyper-
thyroidism.
Another important issue for future study is whether par-
ticular subtypes of depression respond preferentially to
thyroid hormone or in fact any hormonal treatment. As
greater knowledge is obtained about genetic and bio-
logical variability of major depression as well as the reg-
ulation of thyroid hormones in the body in general and
the brain in particular, we may be able to identify pref-
erential responders to thyroid hormone and, analo-
gously, to other hormone strategies.
Gonadal hormones
Testosterone
There are several lines of evidence, both clinical and
research, that support the idea that testosterone and sim-
ilar androgens may be useful in the treatment of
depressed men. First, hypogonadism, usually pharmaco-
logically induced, is associated with depressive symp-
toms and low libido,
52,53 and androgen replacement is
often associated with improvement in mood, energy, and
libido
54-56 in some but not all studies, although this litera-
ture is also inconsistent.
57,58 Second, some but not all
studies suggest an association between low testosterone
levels and depressive symptoms.
59,60 Last, supraphysio-
logical doses of androgens may be associated with manic
or hypomanic symptoms in some individuals,
61 and
hypogonadism during withdrawal from long-term ana-
bolic steroid use may be associated with depression.
61
These observations have led to numerous studies exam-
ining the effect of androgens in the treatment of depres-
sion. Earlier, open-label studies suggested that andro-
gens may be effective for treating depression, especially
in men who are hypogonadal.
62-65 Recently, there have
been several studies using controlled designs where
testosterone was used to treat depression in men who
were hypogonadal or had low normal levels of testos-
terone. Testosterone was administered as monotherapy
or else as an adjunct to conventional antidepressants.
These studies are summarized in Table VI. The findings
from these studies are inconsistent, producing positive,
negative, and inconclusive results.
66-74 Some of these dif-
ferences may be due to methodological issues as noted
in Table VI, although the weight of evidence would sug-
gest that testosterone may have some antidepressant
benefits in hypogonadal men. Further study is required
before definitely concluding that testosterone is a clini-
cally useful treatment for depression. The limited data-
base and inconclusive findings in some studies have to
be weighed against the known side effects of testos-
terone administration such as hypertension, gyneco-
mastia, and polycythemia as well as the fact that treat-
ment emergent paranoid symptoms have been
infrequently reported especially in earlier studies.
62-65The
potential increased risk for prostate cancer with long-
term testosterone treatment remains an unresolved
issue.
75,76
Ovarian hormones
The neuromodulatory effects of the ovarian steroids are
well established.
77-79 Substantial changes in estrogen lev-
els can have effects on brain function and, therefore, on
mood and cognition.
79 The cyclic changes in gonadal
steroids that occur with the menstrual cycle is one exam-
ple of a period of vulnerability for psychiatric symptoms
as a consequence of these fluctuations.
80 It follows that
depressive symptoms and depressive disorders occur at
important stages of a women’s life at times when the
reproductive cycle is associated with changes in ovarian
hormone levels, thus providing a rationale for the use of
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menstrual depression, there is also greater vulnerability
to depression in the postpartum and peri/post-
menopausal period. Each will be briefly reviewed.
Premenstrual depressive symptoms
Most women will report premenstrual symptoms at
some point in their lives.
81About one fifth of women will
report more severe symptoms, including depression, and
about 3% to 8% will meet criteria for the diagnosis of
Premenstrual Dysphoric Disorder (PMDD).
82 A wide
variety of treatment options have been utilized for
patients where symptoms interfere with daily function
or quality of life. These are not limited to pharmacolog-
ical options, and hormonal treatment represents a very
small component of the overall approach to this condi-
tion.
83 Hormonal therapy of premenstrual symptoms
involves suppression of ovulation by using oral contra-
ceptives,
83 gonadotrophin-releasing hormone agonists
(GnRH agonists), and danazol in order to break the
cyclic recurrence of mood symptoms. These are usually
employed when standard antidepressant treatments are
ineffective.
83 GnRH agonists have been shown to be
variably effective in reducing psychiatric morbidity in
several placebo-controlled trials.
84-86 For the most part
these studies have varying methodological limitations.
84-86
In addition, side-effect burden is a problem with the
GnRH agonists, particularly those relating to hypoe-
strogenism which are only partially ameliorated by add-
back estrogen and progestogen therapy.
84-86The reduc-
tion in bone mass with these compounds limits duration
of treatment to no more than 6 to 9 months.
83
Various formulations of oral contraceptives have been
used to treat premenstrual symptoms. In general, these
have had mixed results in improving these symptoms in
open and controlled trials.
87-90The general consensus is that
oral contraceptives of any formulation are more likely to
be beneficial in treating physical symptoms of premen-
strual syndrome and have less demonstrated efficacy with
depressive and related psychiatric symptoms.
87-90
Danazol is an androgen-like agent which inhibits
gonadotropin release and, thereby, ovulation, and has
been shown in several controlled trials to reduce symp-
toms of premenstrual syndrome.
91-93 However, its andro-
genic side effects, particularly masculinization, as well as
Pharmacological aspects
132
Study Subjects Design Testosterone Antidepressant Result
Seidman and Rabkin, 1998
66 5 men  Open  400 mg im biweekly Yes Marked improvement
Low testosterone levels 8 weeks
Seidman et al, 2001
67 32 men RCT  200 mg im q-weekly Yes Testosterone=Placebo
Hypogonadal 6 weeks
Perry et al, 2002
68 16 Open 200 mg vs 100 mg qweekly No No dose effect 
Older males 6 weeks Improvement late onset > 
early onset depression
Pope et al, 2003
69 22 RCT Gel 1% 10 g/day Yes Testosterone>placebo
Low testosterone levels 8 weeks
Orengo et al, 2005
70 61 RCT Gel 1% 5 g/day Yes Testosterone=placebo
Hypogonadal men >50 y 12-week crossover
Seidman et al, 2005
71 26 RCT im Yes Testosterone=placebo
Healthy adult men 6 weeks
Seidman et al, 2009
72 23 RCT im q10 days No Testosterone>placebo
Men, low testosterone 6 weeks
Dysthymic
Shores et al, 2009
73 33 RCT Gel 1% 7.5 g/day Yes Testosterone>placebo
Men >50 y hypogonadal 12 weeks
Dysthymic
Pope et al, 2010
74 100
Adult men RCT Gel 1% Yes Testosterone=placebo
Low testosterone levels 6 weeks
Table VI. Testosterone treatment of depression.
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seriously limits its clinical utility.
91-93
Postpartum depression
The postpartum period is characterized by a sharp
reduction in circulating estrogen levels, which provides
a rationale for the use of estradiol to treat this disorder.
A recent open and controlled trial provided support for
the efficacy of estradiol therapy.
94,95 In the open trial, 21
of 23 postpartum severely depressed women responded
to sublingual 17b-estradiol (4.8 mg/d) for 8 weeks.
94 In
the controlled trial, where subjects received high dose
transdermal 17b-estradiol (200  g/d) for 6 months in
addition to antidepressants, the active treatment had a
significantly greater antidepressant effect compared with
placebo over the course of treatment.
95
Perimenopausal/postmenopausal period
During this life phase, there is an increasingly erratic
cyclic variation in estrogen and progestogen followed by
increasing periods of estrogen withdrawal. During this
phase there is a significant increase in the risk for major
depression, especially in those women who have a past
history of depressive episodes.
96As with any other stage
of life, treatment of depressive disorder in the peri- and
postmenopausal period usually involves antidepressant
treatment. However, given that this phase of life is asso-
ciated with progressive ovarian failure and hypoestro-
genism, the role of estrogen replacement therapy in the
treatment of depression has been a focus of research.
97-101
In some but not all open-label and placebo-controlled
studies,
97-101 estrogen has been shown to reduce both phys-
ical and depressive symptoms. In particular, two of three
recent controlled trials
99-101 documented the efficacy of
estrogen replacement therapy in reducing depression in
postmenopausal women. Estrogen replacement therapy
may also enhance antidepressant response in such
women.
The potential clinical efficacy of estrogen in postpartum
and postmenopausal depression, or in any other psychi-
atric indications associated with altered gonadal func-
tion, has to take side effects into consideration.
83-101
Common side effects include gastrointestinal dysfunc-
tion, headaches, and exacerbation of migraine as well as
breast tenderness, vaginal bleeding, and infection.
Hypertension and venous thrombosis are also concerns,
although this risk is potentially reduced by use of trans-
dermal rather than oral estrogen preparations.
83-101 The
relationship between estrogen therapy and risk of breast
and uterine cancer is beyond the scope of this review, but
remains an issue to consider in instituting estrogen treat-
ment for these various depressive syndromes.
Pineal gland
Melatonin is the major secretory hormone of the pineal
gland. One of the main physiological effects of mela-
tonin is the regulation of circadian rhythms.
102 Given the
prominence of sleep disturbance and the demonstrated
alteration of various circadian parameters in major
depression,
103 several studies have attempted to deter-
mine whether a specific abnormality of melatonin secre-
tion could be demonstrated in major depression and, fur-
ther, whether it could be of potential etiological
significance.
104 Findings from these studies have been
inconsistent with many showing decreased amplitude of
the nocturnal surge of melatonin while others showed
increased or no change in nocturnal melatonin secre-
tion.
104 The-well described sedative effect of this hor-
mone and its effect on circadian function has led to its
widespread use in insomnia, jet lag, and difficulties asso-
ciated with shift work.
105
The use of melatonin as an antidepressant has been
examined in both seasonal and nonseasonal depression.
In seasonal depression, although a normalizing phase
advance has been consistently demonstrated, the anti-
depressant action of melatonin has been inconsis-
tent.
106,107 In seasonal depression, the first report actually
demonstrated worsening of depressive symptoms in a
study of 6 depressed subjects given intravenous mela-
tonin at varying but usually high doses.
108 This study
abated enthusiasm for examining the antidepressant
effects of melatonin for some time, but a subsequent
group of better designed studies have emerged. These
are summarized in Table VII. These studies continue to
document the hypnotic effects of melatonin, but produce
inconsistent findings as far as antidepressant effects are
concerned. The studies do however, involve small sam-
ples and limited follow-up, making it difficult to reach a
definitive conclusion about the clinical efficacy of mela-
tonin as an antidepressant. Further study is necessary to
definitively assess the extent of the antidepressant effect
of melatonin and its potential role relative to standard
antidepressant treatments.
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agomelatine, acting at both the melatonin-1 and mela-
tonin-2 receptor, is the first melatonergic agonist to have
been developed as an antidepressant. This compound
resynchronizes circadian rhythms which have been
altered in animal models, and also normalizes circadian
rhythms in depressed subjects.
115 It has been shown to
have acute antidepressant effects superior to placebo
and comparable to, or even more favorable than, stan-
dard antidepressants such as sertraline, fluoxetine, and
venlafaxine in several controlled trials.
115-118 It is also gen-
erally well tolerated. Agomelatine may not only repre-
sent a new class of antidepressant with a different toler-
ability profile, but it may also provide indirect evidence
that melatonin may be involved in the cascade of bio-
logical events associated with the etiology and treatment
response of major depression.
Adrenal axis hormones
There is a well-described relationship between hyper-
cortisolism and depressive symptoms in both psychiatric
and endocrine patients.
119 Approximately half of all
severely depressed subjects have elevated levels of cor-
tisol,
119 and depression is a frequent complication of both
Cushing’s syndrome as well as with longer-term treat-
ment with exogenous corticosteroids.
119 These observa-
tions have led to the notion that interference with corti-
sol secretion may produce antidepressant effects. This
approach to hormonal treatment of depression involv-
ing the adrenal axis means reducing the levels and
effects of adrenal hormones rather than enhancing hor-
mone levels by exogenous administration as has been
discussed with the other hormonal systems. 
Major depression may be associated with a defect at or
above the level of the hypothalamus resulting in the
hypersecretion of corticotrophin-releasing hormone
(CRH) and, therefore, leading to hypercortisolism.
119
Various strategies to reduce adrenal function have been
undertaken starting with a variety of antiglucocorticoid
agents. Several antiglucocorticoid drugs have been stud-
ied in depressed patients: including cortisol synthesis
inhibitors such as metyrapone, aminoglutethimide, and
ketoconazole. The glucocorticoid receptor antagonist
mifepristone (RU486) has also been examined mostly in
psychotic depression and, recently, there has been an
effort to develop CRH receptor antagonists for clinical
use.
With regard to ketoconazole, Murphy et al
120 reported
six responders and two partial responders to ketocona-
zole in a case series of 10 patients with major depression
who did not respond to standard antidepressants.
Several case reports and small-open label studies have
provided replication of these initial findings.
121-123
However, as with other cortisol synthesis inhibitors there
is a lack of controlled trials with acceptable clinical trial
methodology, although in the case of metyrapone, there
is limited evidence for antidepressant effects in small
placebo-controlled studies.
124,125
Mifepristone (RU486) has also been studied as an anti-
depressant, primarily in the treatment of psychotic
depression.
126,127This compound is a competitive inhibitor
of the glucocorticoid receptor. Mifepristone has been
shown in small open as well as controlled studies to
reduce psychotic symptoms in patients treated for major
depression.
126,127 The therapeutic effect on depressive
symptoms is not as substantial. The potential clinical util-
ity of this treatment in this subgroup of depressed sub-
jects who are generally more severely ill and more resis-
tant to standard treatments requires further study. 
In recent years there has been a substantial initiative to
develop compounds which act as antagonists at the CRH1
Pharmacological aspects
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Study N Melatonin dose  Duration Design Result
(mg/day)
Carman et al, 1976
108 6 Varying IV Varying Open 3/6 worse depression and sleep
DeVries and Peeters, 1997
109 1 5 1 week Case study Improved depression
Fainstein et al, 1997
110 9 3 3 weeks Open Improved sleep not depression
Dolberg et al, 1998
111 19 5 4 weeks RCT-adjunct to antidepressant Improved sleep, not depression
Dalton et al, 2000
112 8 10 (SR prep) 4 weeks RCT-adjunct to antidepressant Improved sleep, not depression
Serfaty et al, 2003
113 38 6 4 weeks Open Depression improved with melatonin and 
placebo, trend for greater with melatonin 
Bellipanni et al, 2005
114 139 3 6 weeks RCT Melatonin>placebo for depression 
Table VII. Melatonin treatment of depression.
PAGES_11_AG_1040_BA.qxd:DCNS#48  5/03/11  11:37  Page 134receptor.
128,129 Given the overactivity of the adrenal axis in
depression likely related to hypersecretion of CRH, there
is a strong theoretical basis to such an approach. Several
such compounds were discontinued early in drug devel-
opment, due to unacceptable toxicity not necessarily
related to their action at the CRH receptor.
127There are
limited data at this time on those compounds that have
advanced to a later stage of development to determine
whether this group of compounds may ultimately provide
a novel class of antidepressants.
128,129
Conclusion
Standard pharmacological treatment has proven to have
limited efficacy in the treatment of major depression and
related disorders. For example, up to half of patients
treated for major depression will have an antidepressant
response, and only approximately one third will achieve
remission of symptoms.
130
The relationship between endocrine dysfunction and
depression has a long-established history. While psychi-
atric comorbidity is a common feature of many endocrine
disorders, a specific, etiologically significant hormonal
abnormality has been much more challenging to identify
in major depression. Nonetheless, there has been a con-
certed effort to utilize hormonal treatments for patients
with primary major depression, particularly those with
illness refractory to standard treatment or where there
are special circumstances to justify use, eg, the postpar-
tum period or hypogonadal men. Our review confirms
that results have been mixed and even a strong theoret-
ical rationale does not necessarily ensure robust clinical
findings. With most hormonal treatment studies, there
have been methodological limitations, particularly small
samples and a lack of randomized controlled trials. With
the possible exception of tri-iodothyronine, few of these
treatments have achieved even limited clinical utility and
the potential of others, based on strong theoretical ratio-
nale, eg, CRH1 receptor antagonists, have yet to reveal
their potential. Nonetheless, these studies, beside their
potential clinical applicability, also provide important
insight into the biological basis of mood disorders and the
role of various hormonal systems in their etiology and
treatment. ❏
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